Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Published Only

The New Paradigm of Diabetes Care

  1. SAAD SAKKAL
  1. Milton, FL
Diabetes 2018 Jul; 67(Supplement 1): -. https://doi.org/10.2337/db18-2270-PUB
Previous
  • Article
  • Info & Metrics
Loading

Abstract

Background: Achieving targets in diabetes care is still an elusive dream since < 54% reach HgA1c<7%. Is there a better paradigm? CGMS has proven its excellent data and analytics value.The Virtual Pancreas System (VPS) has proven its therapeutic value, by reaching Targets in >% 80, to achieve the triple aim of optimum HgA1c/glucose variability, zero hypoglycemia or weight gain,it is now cloud-based, reachable by any mobile or internet as a VPS/metabolic simulator. The value index is how much money ($) is spent on improving HgA1c 1% in three months

Methods and Design: We compared, using the value index, in 10 matched patients the standard paradigm (SP) and the new CGMS/VPS paradigm. We projected savings on total diabetes care for 10 million people with diabetes. We present data for both paradigms and consider the better option.

Results: CGMS/VPS lowered HgA1c by the absolute value of 2.4% and the relative value of 2.7% when compared to standard paradigm(SP), which is better than many newer standard medications (DPP-4 lowers HgA1c by an average of 0.5%, SLGT2: 0.8-1, Dulaglutide: 1.08). With CGMS/VPS the glucose in targets was 82%, FBS was 123, PPG 154, hypoglycemia 0.8%, and weight -5 lbs, the value index was $236 per quarter.In standard care, the glucose in the target was 66%, FBS 148, PPG 186, and weight +6 lbs, and the value index was $1400 per quarter.

Conclusion: CGMS/VPS is a superior new paradigm.Here is how I envision the new brave world of diabetes care in the future: 1) each patient registers through their medical home, to the cloud-based VPS with secure password, with CGMS daily data transmission 2) Patients and providers receive instant feedback to act. 3)diabetologists supervise the process, consult and advice when necessary. 4) The goal of optimum diabetes care is reached with optimal HgA1C, optimal weight, and no hypoglycemia with quarterly CGMS. 5) This new paradigm will cut the burden of the diabetic epidemic scourge by 30 Billion/year; we could prove it by initiating real-life large multi-center studies. This should be the new paradigm: promising and achievable.

Disclosure S. Sakkal: None.

  • © 2018 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

Previous
Back to top
Diabetes: 67 (Supplement 1)

In this Issue

July 2018, 67(Supplement 1)
  • Table of Contents
  • Index by Author
  • Abstract PDFs
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The New Paradigm of Diabetes Care
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The New Paradigm of Diabetes Care
SAAD SAKKAL
Diabetes Jul 2018, 67 (Supplement 1) 2270-PUB; DOI: 10.2337/db18-2270-PUB

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

The New Paradigm of Diabetes Care
SAAD SAKKAL
Diabetes Jul 2018, 67 (Supplement 1) 2270-PUB; DOI: 10.2337/db18-2270-PUB
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics

Related Articles

Cited By...

More in this TOC Section

Published Only

  • A Novel Role of Growth Differentiation Factor 3 for the Regulation of Muscle Metabolism
  • Neudesin, a Novel Regulator of Energy Metabolism in Obesity and Type 2 Diabetes Mellitus—The Effect of Acute Fasting and Endoscopic Duodenal-Jejunal Bypass Liner Implantation
  • Cornus Officinalis Increases Proliferation, Inhibits Cytokine-Induced Apoptosis, and Promotes the Oxidative Capacity of the Human 1.1B4 Pancreatic Cell Line
Show more Published Only

Clinical Diabetes/Therapeutics

  • The Effect of Efpeglenatide on Lipid Profiles and Overall Metabolism in Patients with Type 2 Diabetes and Obese Patients without Diabetes
  • Clinical Outcomes of Patients with Type 2 Diabetes Treated with Multiple Daily Injection (MDI) of Insulin—A Retrospective Cohort Analysis
  • Country-Wide Capacity Building Model in Gestational Diabetes Management for Primary Care Physicians in India
Show more Clinical Diabetes/Therapeutics

Clinical Therapeutics/New Technology–Glucose Monitoring and Sensing

  • Effectiveness and Tolerability of Vildagliptin plus Metformin Compared with Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes—A Real-World Study (China PDS)
  • Effectiveness and Tolerability of Vildagliptin plus Metformin Dual Therapy Compared with Insulin Secretagogue plus Metformin Dual Therapy in Patients with Type 2 Diabetes—A Real-World Study (China PDS)
Show more Clinical Therapeutics/New Technology–Glucose Monitoring and Sensing

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.